Systemic Juvenile Idiopathic Arthritis (AOSD) Clinical Trials

Systemic juvenile idiopathic arthritis is fundamentally different from other forms of JIA. While polyarticular and oligoarticular JIA are autoimmune conditions driven by adaptive immunity (T cells, autoantibodies), sJIA is classified as an autoinflammatory disease driven by innate immune cells, particularly monocytes and macrophages, that overproduce interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-18 (IL-18). The disease course is heterogeneous.

The most common symptoms of Systemic Juvenile Idiopathic Arthritis include Daily high-spiking fevers (often 39°C/102°F or higher) with a quotidian pattern, peaking in afternoons or evenings, Salmon-pink, flat, transient rash that appears with fevers and fades when temperature normalizes, Joint swelling and pain, often involving wrists, knees, and ankles, Enlarged liver and spleen (hepatosplenomegaly), Inflammation of the heart or lung lining (pericarditis, pleuritis), among others. Accounts for 10-20% of all juvenile idiopathic arthritis cases; estimated 1 in 32,000 children in the U.S. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Systemic Juvenile Idiopathic Arthritis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Biologic therapy with IL-1 or IL-6 blockade is now considered first-line for active sJIA before chronic joint damage occurs, though insurance and access barriers persist. Ongoing trials are evaluating JAK inhibitors (baricitinib in NCT04088396 and upadacitinib in NCT05609630, each with a tocilizumab comparison arm), IL-18 targeted therapies for MAS prevention, and whether early biologic initiation can prevent the transition to chronic destructive arthritis.

Yes. As of October 21, 2026, 3 FDA-approved medicines have a current label that names Systemic Juvenile Idiopathic Arthritis: Actemra (tocilizumab), first approved in 2010; Gamifant (emapalumab), first approved in 2018; and Ilaris (canakinumab), first approved in 2013. Corticosteroids and immune globulins count once each.

The exact cause of Systemic Juvenile Idiopathic Arthritis is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoinflammatory/autoimmune; HLA and other immune-gene variants shift risk but no diagnostic gene test exists. Accounts for 10-20% of all juvenile idiopathic arthritis cases; estimated 1 in 32,000 children in the U.S. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Systemic Juvenile Idiopathic Arthritis. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoinflammatory/autoimmune; HLA and other immune-gene variants shift risk but no diagnostic gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Systemic Juvenile Idiopathic Arthritis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Systemic Juvenile Idiopathic Arthritis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.